Detection of explosives vapors is an extremely difficult task. The sensitivity of currently constructed detectors is often insufficient. The paper presents a description of an explosive vapors concentrator that improves the detection limit of some explosives detectors. These detectors have been developed at the Institute of Optoelectronics. The concentrator is especially dedicated to operate with nitrogen oxide detectors. Preliminary measurements show that using the concentrator, the recorded amount of nitrogen dioxide released from a 0.5 ng sample of TNT increases by a factor of approx. 20. In the concentrator an induction heater is applied. Thanks to this and because of the miniaturization of the container with an adsorbing material (approx. 1 cm3), an extremely high rate of temperature growth is achieved (up to 500 °C within approx. 25 s). The concentration process is controlled by a microcontroller. Compact construction and battery power supply provide a possibility of using the concentrator as a portable device.
Atopic dermatitis (AD) is the most frequent allergic disease in dogs. AD can be treated using allergenspecific immunotherapy as well as symptomatic antipruritic treatment including the use of lokivetmab - caninized anti-interleukine-31 antibody.
The aim of the study was to evaluate the effectiveness of lokivetmab over 12 weeks of treatment. Studies have been carried out in 89 dogs. In all affected animals, the severity of lesions was assessed using the CADESI 04 and the pruritus was assessed using the VAS.
After the first dose of lokivetmab, both CADESI 04 and VAS statistical decreased by 4 weeks from 40.48 to 20.31, and from 7.42 to 2.48, respectively (p = 0.0000001) maintained significantly decresed values during the whole treatment period (CADESI 04 15.64, 15.07 after 8 and 12 weeks, respectively, PVAS 2.03, 1.95 after 8 and 12 weeks, respectively).
Lokivetmab leads to a significant reduction of CADESI 04 and pruritus, within four weeks and maximum effect is achived after the second dose.